Cellular Biomedicine Group Inc (CBMG) was Initiated by Maxim Group to “Buy” and the brokerage firm has set the Price Target at $16. Maxim Group advised their investors in a research report released on Sep 22, 2016.
Cellular Biomedicine Group Inc opened for trading at $14.35 and hit $14.49 on the upside on Tuesday, eventually ending the session at $14.28, with a gain of 0.42% or 0.06 points. The heightened volatility saw the trading volume jump to 7,694 shares. Company has a market cap of $201 M.
In a different news, on Apr 14, 2016, Wei (william) Cao (director) sold 10,000 shares at $17.15 per share price. According to the SEC, on Nov 20, 2015, Wen Tao Liu (Executive Chairman) sold 11,000 shares at $25.00 per share price.
Cellular Biomedicine Group Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of new treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company’s technology includes two r cell platforms: Immune Cell therapy for treatment of a range of cancers using Tcm TCR clonality CAR-T and anti-PD-1 technologies human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases. It is focused on developing and marketing cell-based therapies based on its cellular platforms to treat serious chronic and degenerative diseases such as cancer orthopedic diseases (including osteoarthritis and tissue damage) various inflammatory diseases and metabolic diseases. It is conducting clinical studies for two stem cell based therapies to treat knee osteoarthritis (KOA) and Cartilage Defect (CD). It is conducting preclinical studies in Asthma and Chronic Obstructive Pulmonary Disease (COPD).